M. Coffey

Publications140
h-index24
Citations3,306
Highly Influential Citations105
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • R. Vile
  • 270 Publications, 10,581 Citations
  • H. Pandha
  • 414 Publications, 9,018 Citations
  • A. Melcher
  • 179 Publications, 5,782 Citations
  • K. Harrington
  • 638 Publications, 15,776 Citations
  • Publications
  • Influence
The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus
NIH‐3T3 cells, which are resistant to reovirus infection, became susceptible when transformed with activated Sos or Ras. Restriction of reovirus proliferation in untransformed NIH‐3T3 cells was not… Expand
  • 505
  • 30
  • PDF
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade
Intravenous infusion of oncolytic reovirus in patients leads to infection of brain tumors, infiltration by cytotoxic T cells, and up-regulation of PD-L1. Viruses team up with cancer immunotherapy… Expand
  • 150
  • 13
  • PDF
Reovirus therapy of tumors with activated Ras pathway.
Human reovirus requires an activated Ras signaling pathway for infection of cultured cells. To investigate whether this property can be exploited for cancer therapy, severe combined immune deficient… Expand
  • 686
  • 12
A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.
Reovirus is an oncolytic virus with activity in in vivo models of malignant gliomas (MGs). The primary aims were to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of… Expand
  • 210
  • 8
Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells
BackgroundReovirus type 3 Dearing strain (ReoT3D) has an inherent propensity to preferentially infect and destroy cancer cells. The oncolytic activity of ReoT3D as a single agent has been… Expand
  • 90
  • 5
Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses
Oncolytic viruses (OVs) are unique anticancer agents based on their pleotropic modes of action, which include, besides viral tumor cell lysis, activation of antitumor immunity. A panel of diverse… Expand
  • 48
  • 4
Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.
Oncolytic reovirus can be delivered both systemically and intratumorally, in both preclinical models and in early phase clinical trials. Reovirus has direct oncolytic activity against a variety of… Expand
  • 123
  • 3
Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence
Tumor recurrence represents a major clinical challenge. Our data show that emergent recurrent tumors acquire a phenotype radically different from that of their originating primary tumors. This… Expand
  • 39
  • 3
Systemic reovirus therapy of metastatic cancer in immune-competent mice.
The human reovirus is an oncolytic virus that specifically targets cancer cells with an activated Ras pathway. Because it is replication competent and highly specific for cancer cells, this virus has… Expand
  • 148
  • 2
  • PDF
Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy
Purpose: To test combination treatment schedules of reovirus and radiation in human and murine tumor cells in vitro and in vivo. Experimental Design:In vitro cytotoxicity and cell cycle effects of… Expand
  • 98
  • 2